We are live on ! Find out more
CRBP icon

Corbus Pharmaceuticals
CRBP

107 hedge funds and large institutions have $88.4M invested in Corbus Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 37 increasing their positions, 22 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

73% more capital invested

Capital invested by funds: $51.1M → $88.4M (+$37.3M)

68% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 22

8% more call options, than puts

Call options by funds: $2.56M | Put options by funds: $2.38M

5% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 19

0% more funds holding

Funds holding: 107 → 107 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.39% less ownership

Funds ownership: 1.56% → 1.17% (-0.39%)

Holders
107
Holders Change
–
Holders Change %
0%
% of All Funds
1.88%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
20
Increased
37
Reduced
22
Closed
19
Calls
$2.56M
Puts
$2.38M
Net Calls
+$182K
Net Calls Change
-$427K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$7.04M
2
IEFM
IQ EQ Fund Management
Ireland
+$4.61M
3
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
+$2.95M
4
IC
Ikarian Capital
Texas
+$1.81M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.12M

Top Sellers

Rank Fund Capital Flow
1
EMG
ETF Managers Group
New Jersey
-$4.56M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$3.36M
3
HF
HRT Financial
New York
-$1.68M
4
Renaissance Technologies
Renaissance Technologies
New York
-$1.2M
5
Squarepoint
Squarepoint
New York
-$363K
Name Holding Trade Value Shares
Change 		Change in
Stake
SFPG
101
Stonebridge Financial Planning Group
Florida
$1K – – –
TC
102
Trust Company
Kansas
$1K – – –
EP
103
Eudaimonia Partners
Tennessee
$1K +$1.12K +17 New
SM
104
SG3 Management
Puerto Rico
$1K +$1.12K +17 New
AIG
105
American International Group
New York
$88 +$263 +4 +0.3%
SWM
106
Sugarloaf Wealth Management
Georgia
$2 +$2.17K +33 New
Renaissance Technologies
107
Renaissance Technologies
New York
– -$1.2M -32,070 Closed
Squarepoint
108
Squarepoint
New York
– -$363K -9,684 Closed
Arrowstreet Capital
109
Arrowstreet Capital
Massachusetts
– -$184K -4,893 Closed
WG
110
Winton Group
United Kingdom
– -$58K -1,558 Closed
WC
111
Wexford Capital
Florida
– -$32K -852 Closed
DADC
112
D.A. Davidson & Co
Montana
– -$27K -724 Closed
Vontobel Holding
113
Vontobel Holding
Switzerland
– -$26K -685 Closed
JG
114
Jefferies Group
New York
– -$25K -667 Closed
Millennium Management
115
Millennium Management
New York
– -$22K -596 Closed
QT
116
Quantbot Technologies
New York
– -$21K -562 Closed
RJFSA
117
Raymond James Financial Services Advisors
Florida
– -$21K -551 Closed
Russell Investments Group
118
Russell Investments Group
United Kingdom
– -$17K -470 Closed
RIA
119
Realta Investment Advisors
Delaware
– -$13K -333 Closed
ASN
120
Advisory Services Network
Georgia
– -$9K -233 Closed
HCM
121
Horrell Capital Management
Arkansas
– -$8K -33 Closed
TWM
122
Tradition Wealth Management
Minnesota
– -$1K -17 Closed
IF
123
Ironwood Financial
Arizona
– +$66 +1 New
1 2 3 4
5

CRBP Hedge Fund Activity: Q1 2021 in Review

107 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q1 2021, worth a combined $88.4M — up 73% from $51.1M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new CRBP positions and 19 closed out — a net gain of 1 holder — while 37 added to existing stakes and 22 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $7.04M. The largest seller was ETF Managers Group, cutting an estimated $4.56M.

  • 107 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q1 2021, unchanged from Q4 2020.
  • Funds reported $88.4M of Corbus Pharmaceuticals stock for Q1 2021, up 73% quarter-over-quarter.
  • 20 funds opened new Corbus Pharmaceuticals positions in Q1 2021 and 19 closed out, a net change of +1 holder.
  • The largest Corbus Pharmaceuticals buyer in Q1 2021 was Morgan Stanley, an estimated $7.04M added.
  • The largest Corbus Pharmaceuticals seller in Q1 2021 was ETF Managers Group, an estimated $4.56M sold.

Based on aggregated 13F filings for Q1 2021.